Normon begins a new chapter under the general management of jesús govantes garcía

Normon, a Spanish pharmaceutical company with over 85 years of history, announced on March 1 the appointment of Jesús Govantes García as its new CEO. This appointment comes at a key moment for the company, which is also undergoing a transformation in its organization and corporate identity.

With a background in pharmacy, Jesús Govantes García has built a solid career in the sector, with over 10 years of experience as International Director at Normon. In this role, he has played a key part in the company’s expansion into new markets, developing strong competencies in leadership, business management, and strategic decision-making. His profile combines a deep understanding of the pharmaceutical sector with a global perspective and an efficiency-oriented approach.

In the words of Jesús Govantes García, “It is an honor to assume the role of CEO and to continue our family’s legacy. Our commitment to healthcare professionals and patients remains our top priority. We will continue working to ensure access to quality treatments, as we face the new challenges of the sector”.

Jesús Govantes Esteso, who served as President and CEO until February 28, will continue as Chairman of the company. In addition, Gonzalo Fernández Govantes takes on the role of Deputy General Manager and Director of Operations and R&D.

These appointments mark the beginning of a new chapter in which the family-owned company reaffirms its commitment to trust, closeness, and quality.

HEALTH, OUR PATH

Since 1937, when a small pharmacy in Seville laid the foundations of what is now Normon, the company has grown to become a benchmark in the pharmaceutical sector. With a presence in over 90 countries and one of the most advanced facilities in Europe, it continues to promote access to quality treatments.

In 2024, Normon produced over 345 million units and nearly 5 billion doses at its facilities in Tres Cantos (Madrid), where more than 3,200 professionals work each day with a clear purpose: caring for people’s health. Every second, four Normon treatments are dispensed in pharmacies across Spain, highlighting the impact of its vade mecum of generic medicines, the most extensive on the market. In addition, its hospital line is present in nearly all clinics and hospitals across the country, holding a 19.1% share of units in the hospital market.

For over 30 years, Normon has supported dentists with a wide range of specific products. One in every two patients is treated with its dental anesthesia, reinforcing its position as a leader in the sector.

Normon OTC continues to evolve to offer solutions that promote wellness and self-care, establishing itself as a key pillar for the company’s future.

Press contact comunicacion@normon.com